Trial reportDrug and alcohol dependence2021
Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone.
Trial report in Drug and alcohol dependence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Opioid agonist treatment for people who are dependent on pharmaceutical opioids.The Cochrane database of systematic reviews · 2022Pooled it
- Trial
- Provider experiences delivering collaborative care for co-occurring opioid and mental health disorders: a qualitative study.Family practice · 2025Trial
- Cognitive behavioral therapy for anxiety and opioid use disorder: Development and pilot testing.Journal of substance use and addiction treatment · 2024Trial
- Differential associations between social determinants of health and the initiation of medications for opioid use disorder across care settings.npj health systems · 2026Article
- Unemployment & opioid use disorder - socio-medical assessment results by the Medical Service of the German Federal Employment Agency.Substance abuse treatment, prevention, and policy · 2026Article
- Article
- The impact of collaborative care on perceptions of treatment across racial and ethnic groups.Frontiers in health services · 2026Article
- Persisting high rates of mental health disorders in patients in opioid agonist treatment-Results from a 6-year longitudinal study.The American journal on addictions · 2026Article
- Mental Health Care for Patients with Opioid Use Disorder and Methamphetamine Use in Methadone Maintenance Treatment: Experiences and Perspectives.International journal of mental health and addiction · 2025Article
- Reliability and clinical utility of heroin craving questionnaire factors in treatment-enrolled individuals with opioid use disorder.Drug and alcohol dependence · 2025Article
- Comparing quality of life methadone and buprenorphine for opioid substitution treatment in Iran.Scientific reports · 2025Article
- Healthcare utilization trends among patients with opioid use disorder in U.S. Hospitals: an analysis of length of stay, total charges, and costs, 2005-2020.BMC health services research · 2025Article
- Association Between Opioid Use Disorder and Healthcare Spending and Utilization in Emergency Surgical Patients: A Retrospective Analysis Using Commercial Claims.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2025Article
- Impact of Co-Occurring Psychiatric Comorbidities and Substance Use Disorders on Outcomes in Adolescents and Young Adults with Opioid Use Disorder: A Retrospective Cohort Study.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Sex disparities in outcome of medication-assisted therapy of opioid use disorder: Nationally representative outpatient clinic data.Drug and alcohol dependence · 2025Observational
- The impact of opioid analgesics with concomitant antipsychotic use on pain modulation and management in internal medicine: a cross-sequential study protocol.Frontiers in pain research (Lausanne, Switzerland) · 2025Article
- Psychosocial Outcomes Associated with Mobile Health App Use among Medicaid Recipients who Use Substances.Journal of social work practice in the addictions · 2025Article
- Rates of buprenorphine prescribing and racial disparities among patients with opioid overdose.Drug and alcohol dependence reports · 2024Article
- Patterns of care contacts in the final year of life among opioid overdose fatalities in southern Sweden: a latent class analysis.Harm reduction journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundIndividuals treated for opioid use disorder (OUD) have high rates of psychiatric disorders potentially diminishing treatment outcomes. We examined long-term treatment experiences and outcomes by type of psychiatric disorder among participants who participated in the Starting Treatment with Agonist Replacement Therapies (START) study and its follow-up study.
methodsWe categorized the 593 participants who completed the Mini-International Neuropsychiatric Interview (MINI) during the START follow-up study into four mutually exclusive groups to indicate current psychiatric diagnosis: 1) bipolar disorder (BPD; n = 51), 2) major depressive disorder (MDD; n = 85), 3) anxiety disorder (AXD; n = 121), and 4) no comorbid mental disorder (NMD; n = 336). We compared participants' baseline characteristics and treatment outcomes.
resultsGroups with mental disorders had worse substance use outcomes and poorer psychosocial functioning than the NMD group. Participants with BPD had significantly more self-reported days using opioids (Mean: 8.6 for BPD vs. 3.4 days for NMD, p < 0.01) and heroin (Mean: 6.4 for BPD vs. 2.0 for MDD, 3.1 days for NMD, p < 0.05) in the 30 days prior to the final interview. Compared to patients without mental disorders, patients with MDD spent more time engaged with OUD pharmacotherapy during the ∼16-month period between MINI and final interview (mean: 71.6 % vs. 50.6 %; p < 0.001).
conclusionsOur results show that treatment outcomes in individuals with OUD vary by psychiatric comorbidity groups, which supports the need for mental health assessment and treatment for psychiatric conditions in the context of pharmacotherapy for patients with OUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.